Skip to content
Pharmacy Focus cover art

Pharmacy Times

Pharmacy Focus

A Medicine , Health & Fitness and Mental Health podcast

Good podcast? Give it some love!

About the show

The Pharmacy Times® Pharmacy Focus podcast provides the latest industry news and information, thought-leader insights, clinical updates, patient counseling tools, and innovative solutions for the everyday practice and business of pharmacy. Winner of the 2021 Digital Health Media/Publications Audio Merit Award. 

Newest episodes

Program Directors Make the Case for PGY2 Training to Build the Neurology Pharmacy Pipeline

49 min

In this episode of Mind the Meds, host Erica Marini, PharmD, MS, BCPS, speaks with Kat Chester, PharmD, BCCCP, BCGP, FNCS, a PGY2 neurology residency program director at Grady Memorial Hospital in Atlanta, and Michael Armahizer, PharmD, BCCCP, a clinical pharmacy specialist in neurocritical care at the University of Maryland Medical Center. Marini notes that the American Society of Health-System Pharmacists directory lists roughly 6 formal neurology training positions, compared with 55 PGY2 programs in cardiology and 199 in critical care. Both guests came to neurology without dedicated training and describe how their programs grew out of expanding neurology services, institutional support, and a market survey showing demand for neurology-trained pharmacists.Both Chester and Armahizer make the case that a PGY2 offers depth that a short rotation or on-the-job learning cannot. Residents get repeated exposure to complex cases such as refractory status epilepticus and see neurologic care across inpatient and outpatient settings. Chester points to the volume of practice-changing literature and to the share of new FDA approvals related to neurology, which she puts at about 1 in 5 to 1 in 7. Chester and Armahizer note that they expect the greatest growth to be in ambulatory care, driven by antiamyloid therapies, multiple sclerosis disease-modifying therapies, neonatal Fc receptors and complement inhibitors for myasthenia gravis, and new migraine treatments. They name proving return on investment, low awareness of what pharmacists contribute, and a limited workforce as the main barriers.For PGY1 residents weighing the specialty, Chester rejects 3 common misconceptions: that neurology is too niche, too difficult, or short on career opportunities. They both recommend taking a neurology or neurology-adjacent rotation and talking with practicing neurology pharmacists. Midcareer pharmacists can build expertise through protocol work, mentorship programs, organizations such as Cert...

October Neurology News: Huntington Disease Gene Therapy, Remibrutinib in MS, and AI Medical Advice

15 min

In this update episode of Mind the Meds, host Erica Marini, PharmD, MS, BCPS, opens with regulatory news. The FDA accepted uniQure’s application for AMT-130, a gene therapy for Huntington disease, under priority review. An advisory committee meeting is tentatively planned, and a decision is possible in May 2027. AV-1959R (Nuravax, Inc), an investigational amyloid-β vaccine, received fast track designation for preventing Alzheimer disease in cognitively unimpaired individuals with biomarker evidence of amyloid pathology. FDA decisions are expected in November on asundexian (Bayer HealthCare), an oral factor XIa inhibitor for secondary stroke prevention, and cemdisiran (Regeneron), a C5-targeting small interfering RNA for generalized myasthenia gravis. Marini also notes the $5.6 billion acquisition of Option Care, a major infusion provider. The deal is expected to close in early 2027 and could affect outpatient neurology pharmacy teams.On the clinical side, Bristol Myers Squibb reported the death of a patient with multiple sclerosis after its chimeric antigen receptor (CAR) T-cell trials were halted. In the phase 3 REMODEL-1 (NCT05147220) and REMODEL-2 (NCT05156281) trials, the Bruton tyrosine kinase inhibitor remibrutinib (Rhapsido; Novartis) reduced annualized relapse rates by approximately 35% and 31.2% vs teriflunomide (Aubagio; Genzyme Corp), with no liver safety concerns. However, its effect on 3-month confirmed disability progression was not statistically significant. Other studies found: a marginal, likely not clinically relevant, difference in relapse rates between ofatumumab (Kesimpta; Novartis) and ocrelizumab (Ocrevus; Genentech); a higher risk of inflammatory bowel disease with rituximab (Rituxan; Genentech, Biogen; number needed to harm, 131 at 5 years); a negative phase 2 HIMALAYA trial (NCT05237284) of SAR443820 in amyotrophic lateral sclerosis; a higher risk of spontaneous abortion with early pregnancy exposure to anti-CGRP monoclonal antibodies than...

What Cannabis Rescheduling Means for Pharmacists, Patients, and Psychiatric Care

25 min

In this episode of Psychiatric Pharmacy Pulse, host Megan Maroney, PharmD, BCPP, FAAPP, talks with Mary Bridgeman, PharmD, a pharmacist and clinical professor at the Ernest Mario School of Pharmacy at Rutgers, about the federal effort to move cannabis from Schedule I to Schedule III of the Controlled Substances Act. Bridgeman explains that the federal order covers FDA-approved cannabis products and those dispensed under state medical marijuana licenses. Adult-use cannabis, bulk plant material, and synthetically derived THC remain in Schedule I while the broader rescheduling goes through the hearing process. Because state rules vary so widely, Bridgeman says pharmacists in any practice setting should expect questions from patients and colleagues about cannabis use, its legal status, and its potential benefits and harms.Maroney goes over the main CYP interactions for CBD and THC and notes that smoking cannabis induces CYP1A2. Bridgeman adds that pharmacodynamic effects, such as more sedation and anticholinergic effects, matter too. Drawing on Canada’s lower-risk cannabis guidelines, Maroney outlines harm reduction counseling: avoid driving for 6 to 8 hours after inhaling and longer after oral use, delay use until after adolescence, choose lower-potency or higher CBD-to-THC products, and avoid smoking. Bridgeman cites the 2025 SAMHSA National Survey on Drug Use and Health. It estimates that 21 million Americans use cannabis daily or near daily, more than the number who drink alcohol daily, and that 19.3 million had cannabis use disorder in the past year.Maroney also covers higher-risk groups. These include people with severe mental illness, among whom cannabis use rose after recreational legalization, and people who are pregnant or trying to conceive. She cites Danish data showing that 47.4% of patients with cannabis-induced psychosis were later diagnosed with schizophrenia or bipolar disorder. On the positive side, both guests expect rescheduling to lower research bar...

Similar podcasts

All episodes

The newest 50 of 363 episodes

Program Directors Make the Case for PGY2 Training to Build the Neurology Pharmacy Pipeline

49 min

In this episode of Mind the Meds, host Erica Marini, PharmD, MS, BCPS, speaks with Kat Chester, PharmD, BCCCP, BCGP, FNCS, a PGY2 neurology residency program director at Grady Memorial Hospital in Atlanta, and Michael Armahizer, PharmD, BCCCP, a clinical pharmacy specialist in neurocritical care at the University of Maryland Medical Center. Marini notes that the American Society of Health-System Pharmacists directory lists roughly 6 formal neurology training positions, compared with 55 PGY2 programs in cardiology and 199 in critical care. Both guests came to neurology without dedicated training and describe how their programs grew out of expanding neurology services, institutional support, and a market survey showing demand for neurology-trained pharmacists.Both Chester and Armahizer make the case that a PGY2 offers depth that a short rotation or on-the-job learning cannot. Residents get repeated exposure to complex cases such as refractory status epilepticus and see neurologic care across inpatient and outpatient settings. Chester points to the volume of practice-changing literature and to the share of new FDA approvals related to neurology, which she puts at about 1 in 5 to 1 in 7. Chester and Armahizer note that they expect the greatest growth to be in ambulatory care, driven by antiamyloid therapies, multiple sclerosis disease-modifying therapies, neonatal Fc receptors and complement inhibitors for myasthenia gravis, and new migraine treatments. They name proving return on investment, low awareness of what pharmacists contribute, and a limited workforce as the main barriers.For PGY1 residents weighing the specialty, Chester rejects 3 common misconceptions: that neurology is too niche, too difficult, or short on career opportunities. They both recommend taking a neurology or neurology-adjacent rotation and talking with practicing neurology pharmacists. Midcareer pharmacists can build expertise through protocol work, mentorship programs, organizations such as Cert...

October Neurology News: Huntington Disease Gene Therapy, Remibrutinib in MS, and AI Medical Advice

15 min

In this update episode of Mind the Meds, host Erica Marini, PharmD, MS, BCPS, opens with regulatory news. The FDA accepted uniQure’s application for AMT-130, a gene therapy for Huntington disease, under priority review. An advisory committee meeting is tentatively planned, and a decision is possible in May 2027. AV-1959R (Nuravax, Inc), an investigational amyloid-β vaccine, received fast track designation for preventing Alzheimer disease in cognitively unimpaired individuals with biomarker evidence of amyloid pathology. FDA decisions are expected in November on asundexian (Bayer HealthCare), an oral factor XIa inhibitor for secondary stroke prevention, and cemdisiran (Regeneron), a C5-targeting small interfering RNA for generalized myasthenia gravis. Marini also notes the $5.6 billion acquisition of Option Care, a major infusion provider. The deal is expected to close in early 2027 and could affect outpatient neurology pharmacy teams.On the clinical side, Bristol Myers Squibb reported the death of a patient with multiple sclerosis after its chimeric antigen receptor (CAR) T-cell trials were halted. In the phase 3 REMODEL-1 (NCT05147220) and REMODEL-2 (NCT05156281) trials, the Bruton tyrosine kinase inhibitor remibrutinib (Rhapsido; Novartis) reduced annualized relapse rates by approximately 35% and 31.2% vs teriflunomide (Aubagio; Genzyme Corp), with no liver safety concerns. However, its effect on 3-month confirmed disability progression was not statistically significant. Other studies found: a marginal, likely not clinically relevant, difference in relapse rates between ofatumumab (Kesimpta; Novartis) and ocrelizumab (Ocrevus; Genentech); a higher risk of inflammatory bowel disease with rituximab (Rituxan; Genentech, Biogen; number needed to harm, 131 at 5 years); a negative phase 2 HIMALAYA trial (NCT05237284) of SAR443820 in amyotrophic lateral sclerosis; a higher risk of spontaneous abortion with early pregnancy exposure to anti-CGRP monoclonal antibodies than...

What Cannabis Rescheduling Means for Pharmacists, Patients, and Psychiatric Care

25 min

In this episode of Psychiatric Pharmacy Pulse, host Megan Maroney, PharmD, BCPP, FAAPP, talks with Mary Bridgeman, PharmD, a pharmacist and clinical professor at the Ernest Mario School of Pharmacy at Rutgers, about the federal effort to move cannabis from Schedule I to Schedule III of the Controlled Substances Act. Bridgeman explains that the federal order covers FDA-approved cannabis products and those dispensed under state medical marijuana licenses. Adult-use cannabis, bulk plant material, and synthetically derived THC remain in Schedule I while the broader rescheduling goes through the hearing process. Because state rules vary so widely, Bridgeman says pharmacists in any practice setting should expect questions from patients and colleagues about cannabis use, its legal status, and its potential benefits and harms.Maroney goes over the main CYP interactions for CBD and THC and notes that smoking cannabis induces CYP1A2. Bridgeman adds that pharmacodynamic effects, such as more sedation and anticholinergic effects, matter too. Drawing on Canada’s lower-risk cannabis guidelines, Maroney outlines harm reduction counseling: avoid driving for 6 to 8 hours after inhaling and longer after oral use, delay use until after adolescence, choose lower-potency or higher CBD-to-THC products, and avoid smoking. Bridgeman cites the 2025 SAMHSA National Survey on Drug Use and Health. It estimates that 21 million Americans use cannabis daily or near daily, more than the number who drink alcohol daily, and that 19.3 million had cannabis use disorder in the past year.Maroney also covers higher-risk groups. These include people with severe mental illness, among whom cannabis use rose after recreational legalization, and people who are pregnant or trying to conceive. She cites Danish data showing that 47.4% of patients with cannabis-induced psychosis were later diagnosed with schizophrenia or bipolar disorder. On the positive side, both guests expect rescheduling to lower research bar...

Inside the New Consensus Recommendations for Acute Stroke Care

56 min

In this episode of Mind the Meds, host Erica Marini, PharmD, opens with the month's neurology pharmacy news: Novartis and Bristol Myers Squibb paused CAR T-cell trials in autoimmune diseases, including myasthenia gravis and multiple sclerosis, after safety concerns. FDA approvals included tavapadon (Juvmo; AbbVie), a selective D1/D5 dopamine agonist for Parkinson disease; apitegromab (Isembyld; Scholar Rock), an add-on myostatin inhibitor for spinal muscular atrophy; and levacetylleucine (Aqneursa; IntraBio Inc) for ataxia-telangiectasia.  FDA also granted priority review to satralizumab (Genentech) for relapsing myelin oligodendrocyte glycoprotein antibody–associated disease. Currently, it is approved for anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder under the brand name Enspryng. Marini closes the segment with positive results for ulefnersen (Ionis Pharmaceuticals, Otsuka Pharmaceutical) in FUS-ALS in the phase 3 FUSION trial (NCT04768972) and for atogepant (Qulipta; AbbVie) in menstrual migraine prevention. Marini is then joined by Caitlin S. Brown, PharmD, MPH, BCCCP, FCCM, FCCP, associate professor of pharmacy and emergency medicine at Mayo Clinic; and Brian Gilbert PharmD, MBA, FCCM, FNCS, FCCP, FASHP, FKCHP, a former emergency medicine clinical pharmacy specialist. Both are authors of the consensus recommendations on integrating clinical pharmacists into the acute stroke care team, published in the Journal of the American College of Clinical Pharmacy.1 The project grew out of the authors’ systematic reviews on pharmacist involvement in ischemic and hemorrhagic stroke. Their panel brought together emergency medicine and neurocritical care pharmacists from academic and community settings, emergency physicians, a neurologist, a librarian, and a statistician. The recommendations were endorsed by the American College of Clinical Pharmacy, the Neurocritical Care Society, the Society for Academic Emergency Medicine, and the Society of C...

How Community Pharmacies Help Patients Quit Smoking

32 min

Cindy Valencia, PhD, MPH, is director of CA Quits at UC Davis Health Center for Healthcare Policy and Research. They can be found on LinkedIn. Robin Corelli, PharmD, is a professor of clinical pharmacy in the Department of Clinical Pharmacy at the School of Pharmacy of the University of California, San Francisco. You can read their bio here.

Centanafadine May Offer Second-Line Option for Patients With ADHD If Stimulants Fail

25 min

In this episode of Psychiatric Pharmacy Pulse, host Megan Maroney, PharmD, BCPP, FAAPP, speaks with Danielle Stutzman, PharmD, BCPP, clinical assistant professor at the University of Colorado Skaggs School of Pharmacy and assistant adjunct professor at the Child and Adolescent Mental Health Division of the Department of Psychiatry at the University of Colorado School of Medicine, and member of the American Association of Psychiatric Pharmacists Board of Directors, about where centanafadine (Simtriyo; Otsuka Pharmaceutical) fits into attention-deficit/hyperactivity disorder (ADHD) pharmacotherapy. Centanafadine received FDA approval in July 2026 as a norepinephrine-dopamine-serotonin reuptake inhibitor (NDSRI) for ADHD in both pediatric and adult patients, with DEA scheduling still pending. Maroney and Stutzman note its mechanism is not entirely novel, drawing comparisons to tricyclic antidepressants, atomoxetine (Eli Lilly), and viloxazine (Qelbree; Supernus Pharmaceuticals, Inc).  A pooled meta-analysis of 4 phase 3 trials plus a phase 2b crossover study found a Hedges’ g effect size of about 0.37 for overall symptom severity versus placebo, a modest result that falls short of typical stimulant effect sizes of 0.8 to 1.0, though executive functioning outcomes on caregiver-rated scales appeared more promising. Safety data showed a nonsignificant increase in adverse effects (AEs) overall (pooled risk ratio, 1.29), with appetite suppression, nausea, and rash among the most common issues. Rash was the leading cause of study discontinuation in the youngest age group. Indirect comparisons suggested centanafadine may carry a lower risk of insomnia than methylphenidate and fewer AEs than atomoxetine and viloxazine, though lisdexamfetamine (Vyvanse; Takeda Pharmaceuticals) remained more effective. A boxed warning for suicidal ideation applies, which is consistent with other ADHD medications. Practical advantages discussed include a lack of reliance on cytochrome P450 metabo...

Vaccine Timing and Safety in Patients With Neurological Diseases

50 min

This episode of Mind the Meds features guest Patti Yager-Stone, PharmD, BCPS, a clinical pharmacist in neurology at the Veterans Affairs Medical Center in Portland, Oregon, who oversees infusion management and vaccine coordination for about 120 neurology patients. Yager-Stone explains that immunomodulating and immunosuppressant therapies both increase infection risk and can blunt vaccine response, making pretreatment vaccination and timing central to her practice. When vaccination history is incomplete, she recommends avoiding live vaccines in patients on many of these therapies and stresses using serologies and thorough documentation review, instead of patient recall alone. For pneumococcal vaccination, she highlights the CDC's PneumoRecs VaxAdvisor tool for navigating vaccine selection based on patient age and risk conditions. For Yager-Stone’s institution, the 20-valent pneumococcal conjugate vaccine is favored over the 21-valent option for those who are immunocompromised because the latter excludes serotype 4, which is responsible for more than 30% of invasive pneumococcal disease cases in Oregon and several other western states.Marini and Yager-Stone discuss a recent cohort study that eased longstanding concerns about live vaccines, particularly the measles, mumps, and rubella vaccine, triggering relapses in those with multiple sclerosis, a finding both say has reinforced their practice of offering the measles, mumps, and rubella vaccine to patients without documented immunity amid current measles activity. They also note that immunosuppressed patients with measles may present atypically, without the characteristic rash. The conversation also touches on the newly approved mRNA influenza vaccine for patients aged 50 years and older, which showed superior relative efficacy against influenza-like illness compared with standard-dose vaccine in trials; however, higher rates of reactogenic side effects such as fatigue were observed with the vaccine.The episode closes...

Introducing the Psychiatric Pharmacist Pulse Podcast

1 min

Megan Maroney, PharmD, BCPP, FAAPP: Hello, I'm Megan Maroney, and this is Psychiatric Pharmacy Pulse, a monthly podcast where we talk about hot topics in psychiatric pharmacy. I'm a clinical associate professor at the Ernest Mario School of Pharmacy at Rutgers University, and a clinical psychiatric pharmacist at Monmouth Medical Center. I am also a board-certified psychiatric pharmacist and a fellow of the American Association of Psychiatric Pharmacists. So, this podcast is really just a chance to talk about hot topics in psychiatry, new literature coming out, new drugs coming out, things that are coming down the pipeline. We also are going to have guests on the show to discuss these topics. Some of the upcoming episodes we have are on the new [attention-deficit hyperactivity disorder] drug centanafadine (Simtriyo; Otsuka Pharmaceutical) and the rescheduling of cannabis and what that means in terms of pharmacy practice. So, I hope you'll join me for these podcasts and feel free to write in with your ideas for topics and things that you want to hear about and give us feedback. We'd love to hear it. If there’s a topic you want to come on the podcast and talk about, let us know. [I would be] happy to cover things that everyone wants to hear about. To provide feedback or suggest topics of discussion for Psychiatric Pharmacy Pulse, please reach out to Gillian McGovern, Editor (gmcgovern@pharmacytimes.com).

Under the Skin: What Subcutaneous Isatuximab Means for Myeloma Care

31 min

Matthew Lei, PharmD, BCOP, a clinical oncology pharmacist at Massachusetts General Hospital, joins Pharmacy Focus: Oncology Edition to break down the FDA approval of subcutaneous isatuximab-irfc via the CirCLIQ on-body injector, covering the IRAKLIA trial's noninferiority data, the device's practical rollout challenges, and how the agent positions against subcutaneous daratumumab in an increasingly crowded anti-CD38 landscape.

CMSC 2026 Highlights: Biomarkers, DMT Discontinuation, and Pregnancy Planning in MS

54 min

In this episode of Mind the Meds, host Erica Marini, PharmD, MS, BCPS, welcomes Jenelle Hall Montgomery, PharmD, BCACP, CPP, a clinical pharmacist practitioner with Duke Neurological Disorders Clinic at Duke University Hospital, to discuss highlights from the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting in Charlotte, North Carolina, where Montgomery was recognized as a Giant of Multiple Sclerosis. Before the CMSC discussion, Marini runs through a roundup of recent neurology news, including approval of at-home initiation dosing for lecanemab-irmb (Leqembi; Eisai, Biogen), fast track designation for remlifanserin (Acadia Pharmaceuticals) in Alzheimer disease psychosis, approval of the oral PCSK9 inhibitor enlicitide (Lipfendra; Merck), and phase 3 data on tavapadon (AbbVie) for Parkinson disease showing a lower rate of impulse control disorders than traditional dopamine agonists.The pharmacists then turn to CMSC sessions on off-label and evolving areas of MS care. They discuss growing interest in neurofilament light chain as a biomarker for tracking subclinical disease progression over time, along with the ongoing debate over when it is safe to discontinue disease-modifying therapy (DMT) in older, stable patients. Both note their practices generally begin this conversation around 60 to 65 years of age, factoring in radiographic and clinical stability over the preceding decade, and describe strategies such as tapering dosing frequency or switching to lower-efficacy agents rather than abrupt discontinuation.The conversation closes with an update on family planning in MS, where new data presented at CMSC reinforce the safety of anti-CD20 therapies during pregnancy and breastfeeding. Montgomery and Marini review a 10-year dataset of about 5000 pregnancies on ocrelizumab (Ocrevus; Genentech), a large safety analysis of ofatumumab (Kesimpta; Novartis Pharmaceuticals) showing no increase in birth malformations, and early transfer-into-breastmilk data on ubl...

Beyond Seizures: Phenobarbital's Clinically Significant Interaction Profile

53 min

To open the episode, Erica Marini, PharmD, discussed a roundup of FDA and research updates in neurology. She covered the shifting accelerated-approval pathway for AMT-130 (uniQure), a gene therapy for Huntington disease, and a similar back-and-forth for a Hunter syndrome gene therapy. She also noted an expanded indication for olezarsen (Tryngolza; Ionis Pharmaceuticals) in severe hypertriglyceridemia, a UK study linking hypotension to Alzheimer risk, and data suggesting shingles vaccination may lower dementia risk in Medicare beneficiaries. From the American Headache Society meeting, she highlighted phase 2b data on the TRPM8 agonist elismotrep (Kallyope), and the anti-PACAP antibody bocunebart (Lundbeck) for migraine, along with retrospective findings tying CGRP monoclonal antibodies to increased fracture risk and higher odds of spontaneous abortion in early pregnancy.The core interview featured Adrian Wong, PharmD, MPH, BCCCP; and Cayley Krkljes, PharmD, BCPS, of Beth Israel Deaconess Medical Center who discussed a systematic review published in Pharmacotherapy of clinically significant drug-drug interactions with phenobarbital and primidone. Wong and Krkljes described growing use of phenobarbital for alcohol withdrawal and note that health care professionals often underappreciate its interaction potential despite it being a well-known enzyme inducer. Key findings included an induction onset of 24 hours to 30 days and an offset of 2 to 8 weeks, findings that carry particular weight for transitions of care since inpatient dosing effects can persist well after discharge. The most clinically impactful interactions involved anticoagulants (warfarin and direct oral anticoagulants [DOACs]), methadone, and immunosuppressants, with approximately 85% of reviewed studies reporting some outcome impact. They also pushed back on recent social media claims that phenobarbital-DOAC interactions are not clinically relevant, pointing out methodological limitations in the studies be...

World Psychedelics Day: Why Pharmacy Can't Sit This One Out

43 min

Find out more information about the Psychedelic Pharmacists Foundation (PPF) & Psychedelic Pharmacists Association (PPA):PPF: https://www.psychedelicpharmacistsfoundation.org/PPA: https://psychedelicpharmacist.org/

Cancer Prevention, Misinformation, and Modern Wellness

39 min

The discussion examines the evidence behind common concerns about everyday products, food trends, and lifestyle habits, while emphasizing a practical, individualized approach to health and cancer prevention.

Alzheimer Updates, Stroke Breakthroughs, and the Case for Early Treatment

52 min

In this episode of Mind the Meds, Erica Marini, PharmD, highlights information from the European Stroke Organization Conference include encouraging data on asundexian(Bayer), a factor XIa inhibitor showing reduced recurrent ischemic stroke risk without increased bleeding, as well as positive results from three trials of tirofiban in acute ischemic stroke settings. On the multiple sclerosis (MS) front, Marini covers the FDA approval of ocrelizumab (Ocrevus; Genentech) for pediatric relapsing-remitting MS in children 10 and older, a new study supporting early use of high-efficacy agents in pediatric MS, and 2 Lancet publications on ocrelizumab — one examining higher weight-adjusted dosing (which did not improve disability progression) and one confirming benefit in a broader primary progressive MS population. She also briefly discusses PADOVA (NCT04777331), a phase 2b trial of prasinezumab in early Parkinson's disease, which failed to meet its primary end point.The bulk of the episode is a discussion with guest Millad Sobhanian, PharmD, BCPS, clinical pharmacy specialist in neurology at the University of Maryland, focused on Alzheimer disease. They cover dextromethorphan/bupropion (Auvelity; Axsome Therapeutics), newly approved in April 2026 for agitation associated with Alzheimer dementia. Sobhanian walks through key safety considerations—including additive NMDA antagonism if combined with memantine, cardiovascular risks from the bupropion component, and the ever-present black box warning on antipsychotics in dementia patients—while both note that the efficacy data, though statistically significant, shows modest clinical effect sizes compared to the threshold for meaningful within-patient change.The conversation then turns to lecanemab's subcutaneous initiation formulation (Leqembi Iqlik; Eisai, Biogen), whose FDA decision has been delayed to about August 2026 as regulators seek more data on bioavailability and ARIA monitoring in the at-home setting. Sobhanian shares...

Innovations in Psychiatric Pharmacotherapy From the AAPP Annual Meeting

29 min

In this episode of Pharmacy Focus, moderator Bob Haight, PharmD, BCPP, AAPP Annual Meeting director and past president of American Association of Psychiatric Pharmacists (AAPP), discusses the AAPP 2026 Annual Meeting with Archana Jhawar, PharmD, BCPP, clinical assistant professor at the University of Illinois Chicago; and Chelsea Di Polito, PharmD, BCPP, psychiatric clinical pharmacist at the University of Maryland, Baltimore. The discussion centers on emerging trends in psychiatric pharmacotherapy across diverse practice settings. A major focus is on newer psychiatric medications, including sublingual dexmedetomidine for acute agitation, which offers a novel, patient-friendly administration route and potential benefits for inpatient care. Additional discussion covers agents like lumateperone and xanomeline-trospium, with attention to their safety profiles, tolerability, and evolving roles in treatment. The speakers emphasize the importance of real-world experience in determining how these newer therapies fit into clinical decision-making, especially given considerations like cost, monitoring requirements, and patient-specific factors.The episode also explores cutting-edge research and practice challenges, including the growing interest in GLP-1 receptor agonists for substance use disorders. While still considered “unproven but promising,” early data suggest these agents may reduce addictive behaviors by modulating reward pathways rather than through traditional metabolic effects. Additional highlights include evolving strategies for clozapine monitoring following REMS changes, where pharmacists play a central role in balancing safety and access, and advancements in long-acting injectable antipsychotics that improve flexibility, adherence, and patient-centered care. Across all topics, a consistent theme emerges: the expanding range of treatment options requires clinicians to stay informed, adaptable, and focused on individualized care. The speakers conclude that AAP...

Hepatitis B Vaccination in Adults: Overcoming Stigma and Improving Protection

27 min

You can connect with Marilyn Bulloch on LinkedIn here. Read more insights about hepatitis B throughout Hepatitis Awareness Month at Pharmacy Times' Hepatitis Resource Center. Episode Timestamps:1:05: Introduction2:08: Current Disease Burden of Hepatitis B3:55: Risk Landscape for Adults7:20: Link Between Chronic Hepatitis B and Liver Cancer10:25: Expanded Vaccine Recommendations13:25: The Role of Pharmacists in Vaccine Counseling16:40: Why Shorter Conversations Are Better17:55: Advantages of 2-Dose Schedule20:40: Closing the Adult Hepatitis B Immunization Gap23:50: A Patient Counseling Scenario25:25: Closing Thoughts

"I've Been Doing Some Research": Wellness, Mistrust, and the Space Between

47 min

When a cancer patient says "I've been doing some research," the conversation that follows can be just as complex as the treatment itself. In this episode, a malignant hematology clinical pharmacy specialist joins us to unpack health misinformation, AI-generated medical advice, wellness culture, and the controversial therapies oncology patients are bringing into the clinic — and how pharmacists can navigate it all.

Recapping the AAN 2026 Annual Meeting: Neurologic Disease Treatment Is Rapidly Evolving

1 hr 7 min

This inaugural episode of Mind the Meds introduces neurology pharmacy practice through a discussion between 3 neurology pharmacists working across inpatient and outpatient settings at the University of Utah. Host Erica Marini, PharmD, meets with her colleagues, Sarah Dahoney, PharmD, and Tyler Kenny, PharmD, BCCCP, both of whom are clinical pharmacists at the University of Utah Health, to discuss the research presented at the 2026 American Academy of Neurology (AAN) Annual Meeting. After sharing their diverse professional “origin stories,” the conversation then shifts to the role of pharmacists in neurology care and highlights key updates from the American Academy of Neurology annual meeting. The hosts discuss advances in neuromuscular disease, particularly myasthenia gravis, where emerging therapies such as FcRn inhibitors and CAR T-cell therapies are reshaping treatment paradigms. They also explore rare neurological conditions like stiff person syndrome and Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), where early-phase trials suggest promising but still preliminary therapeutic options. Finally, the episode reviews broader neurologic and systemic trends, including GLP-1 receptor agonists and SGLT2 inhibitors, noting potential but not yet definitive benefits in dementia prevention, stroke risk reduction, and migraine outcomes. Across all topics, the episode emphasizes the rapid evolution of neurological therapeutics and the expanding role of pharmacists in maneuvering complex, high-cost, and highly specialized treatments. Key Takeaways: Neurology pharmacy is highly collaborative and evolving, with non-linear career pathways. Pharmacists in neurology often enter the field through diverse experiences rather than a standardized training pipeline, and success depends heavily on adaptability, clinical curiosity, and initiative.  Pharmacists play a critical role in optimizing complex neurological therapies and care transitions. Their contribu...

From Global Insights to the Aisle: Practical OTC Allergy Tips for Pharmacists

25 min

You can find more information about Derek Webb, PharmD, and Dennis Williams, PharmD, BCPS, AEC, below: Derek Webb on LinkedInDennis Williams on LinkedInDennis Williams Faculty Page - UNC Eshelman School of Pharmacy This content was independently developed by Pharmacy Times. While we acknowledge the support of our sponsor, all editorial decisions and opinions remain solely those of Pharmacy Times. Any reference to brands is for informational purposes only and not an endorsement.

Global Lessons From FIP: How Pharmacists Can Elevate OTC Allergy Care

18 min

You can find more information about Derek Webb, PharmD, and Dennis Williams, PharmD, BCPS, AEC, below: Derek Webb on LinkedInDennis Williams on LinkedInDennis Williams Faculty Page - UNC Eshelman School of Pharmacy This content was independently developed by Pharmacy Times. While we acknowledge the support of our sponsor, all editorial decisions and opinions remain solely those of Pharmacy Times. Any reference to brands is for informational purposes only and not an endorsement.

From Underdiagnosed to Under Control: Plozasiran and Pharmacists’ Role in FCS

22 min

On Chen, MD, and Tahmid Rahman, MD discuss how plozasiran—an RNA-based APOC3-targeting therapy for patients with familial chylomicronemia syndrome with infrequent injections and a favorable safety profile—can transform care when integrated through coordinated multidisciplinary workflows with pharmacists leading patient identification, access, and monitoring.

A Silent Killer: Unmasking Radon’s Link to Lung Cancer

39 min

Lung cancer remains one of the leading causes of cancer-related death, yet many cases occur in people who have never smoked. One often-overlooked culprit is radon, a naturally occurring radioactive gas and the second leading cause of lung cancer.

Pharmacy Focus: Role of Pharmacists in Proper Inhaler Usage

23 min

0:48: Intro1:35: Common mistakes with inhalers5:25: Tailoring inhaler education9:10: Selecting the right inhaler for a patient12:05: What an inhaler counseling session looks like15:45: Tracking inhaler technique18:06: Inhaler counseling in community pharmacies21:24: ConclusionJennifer Griffin, PharmD, MS, serves as a clinical pharmacist for Harps Food Stores, Inc., where she specializes in medical billing, point-of-care testing and treatment workflow, and marketing clinical services. She earned her Doctor of Pharmacy degree from Harding University College of Pharmacy in Searcy, Arkansas, and holds a Bachelor of Science in Healthcare Administration and a Master of Science in Health Promotion from the University of Central Arkansas. 

Pharmacy Focus: Navigating Seasonal Allergies

30 min

Derek Webb, a community pharmacist and Virginia Board of Pharmacy member, provides comprehensive guidance on managing seasonal allergies, distinguishing symptoms, and exploring treatment options.

See all 200 episodes

–

0 ratings from members

5
4
3
2
1

Rate this podcast

Log in to rate and review the shows you listen to.

No reviews yet — be the first member to rate "Pharmacy Focus".

This podcast, its content and its artwork are not owned by, affiliated with, or endorsed by Castquire.

Keep listening

Discover more podcasts like this.

Up next

  1. Nothing queued. Use + Queue on any episode to line it up.

0:00 0:00